Skip to content
AnalystLens

Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2017

Filing Date
Filed February 20, 2018
Period End
December 31, 2017
Security
HALO
One revenue dollarkept$0.20
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jun ’16Jun ’16
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 10-K filed February 20, 2018. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies, built on its rHuPH20 enzyme platform.

Its ENHANZE Technology is licensed to eight collaborators, and its lead proprietary program is PEGPH20, which is in Phase 3 testing (HALO-301) in stage IV pancreatic ductal adenocarcinoma. In 2017 total revenues rose to $316.6 milliona from $146.7 million in 2016, and the company reported net income of $62.97 million, compared with a net loss of $103.0 million in 2016. Results were driven mainly by $202.7 million of revenues under collaborative agreements, including $101.4 million of license revenue from BMS and $40.0 million from Alexion, while royalties grew to $63.5 million and product sales, net, were $50.4 million.

The filing also highlights setbacks in the PEGPH20 program. The SWOG S1313 all-comers trial was stopped after a higher rate of death was seen in the PEGPH20 arm, with median overall survival of 7.7 months versus 14.4 months in the modified FOLFIRINOX arm. Halozyme also reports an accumulated deficit of $522.4 millionb, and it discontinued development of HTI-1511.

Cash, cash equivalents and marketable securities were $469.2 millionc at year-end 2017, and management believes this will fund operations for at least the next twelve months. Debt totals $202.4 million in present value, consisting of a $150 million Royalty-backed Loan and a $55.9 million Oxford/SVB term loan. The company expects Roche and Baxalta to deplete inventory in 2018, which will lower bulk rHuPH20 product sales that year.

Adoption of ASC Topic 606 on January 1, 2018 is expected to have a material impact on reported financials, with license revenues on a pro forma basis of $198.4 milliond and royalty revenues of $68.9 million for 2017. For investors, the key tension is between a much stronger 2017 driven by one-time upfront license fees and the binary, high-risk outcome of the Phase 3 PEGPH20 trial.

Key Highlights

  1. Total revenues rose to $316.6 million in 2017 from $146.7 million in 2016, and the company posted net income of $62.97 million versus a net loss of $103.0 million in 2016.
  2. Revenues under collaborative agreements reached $202.7 million in 2017, including $101.4 million from BMS and $40.0 million from Alexion, reflecting upfront license payments.
  3. Royalty revenue was $63.5 million in 2017, up from $51.0 million in 2016, driven by Herceptin SC, MabThera SC/RITUXAN HYCELA and HYQVIA sales.
  4. Lead program PEGPH20 is in Phase 3 (HALO-301) for stage IV pancreatic cancer; the company projects the target number of PFS events will be reached in Q4 2018.
  5. The SWOG S1313 all-comers trial of PEGPH20 with modified FOLFIRINOX was stopped; median overall survival was 7.7 months in the PEGPH20 arm versus 14.4 months in the control arm.
  6. Cash, cash equivalents and marketable securities were $469.2 million at December 31, 2017, following a May 2017 offering of 11.5 million shares that generated $134.9 million in net proceeds.
  7. Adoption of ASC Topic 606 on January 1, 2018 is expected to materially affect financial statements, with pro forma 2017 license revenues of $198.4 million and royalty revenues of $68.9 million.

Follow one dollar

Of each $1.00 of revenue in FY2017, Halozyme Therapeutics kept $0.20.

  1. Revenue$316.6M100.0%
  2. Cost of revenue−$31.2M9.8%
  3. Gross profit$285.5M90.2%
  4. Operating costs−$204.5M64.6%
  5. Operating income$81.0M25.6%
  6. Interest, other & tax−$18.0M5.7%
  7. Net income$63.0M19.9%
Computed from 10-KFY2017filed February 20, 2018Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2017 revenue went

$316.6M
  • R&D: $150.6M, 48% of revenue
  • Net income: $63.0M, 20% of revenue
  • SG&A: $53.8M, 17% of revenue
  • Cost of revenue: $31.2M, 9.8% of revenue
  • Interest, other & tax: $18.0M, 5.7% of revenue

Kept 20% as net income

Full revenue history →

Financial Statements

FY2017 against FY2016

Line itemFY2017FY2016Change
Revenue$316.61M$146.69M+115.8%
Cost of Revenue$31.15M$33.21M−6.2%
Gross Profit$285.46M$113.48M+151.5%
R&D Expenses$150.64M$150.84M−0.1%
SG&A Expenses$53.82M$45.85M+17.4%
Operating Expenses$235.61M$229.90M+2.5%
Operating Income$81.00M-$83.21M+197.3%
Interest Expense$21.98M$19.98M+10.0%
Net Income$62.97M-$103.02M+161.1%
EPS (Basic)$0.46$-0.81+156.8%
EPS (Diluted)$0.45$-0.81+155.6%
Shares Outstanding (Basic)136.42M127.96M+6.6%
Shares Outstanding (Diluted)139.07M127.96M+8.7%

Frequently Asked Questions

  1. What drove the swing to net income in 2017?

    Revenues under collaborative agreements increased to $202.7 million from $42.3 million in 2016, mainly from upfront license fees of $171.4 million recognized for the 2017 Roche, BMS and Alexion agreements, plus $15.0 million in Janssen clinical milestones. Total operating expenses were $235.6 million, and the company recorded an income tax benefit of $1.4 million.

  2. How much cash does Halozyme have and how long will it last?

    Cash, cash equivalents and marketable securities totaled $469.2 million at December 31, 2017. Management believes this is sufficient to fund operations for at least the next twelve months, but states that existing cash may not be adequate until the company becomes profitable, if ever.

  3. What are the main risks to the PEGPH20 program?

    The filing cites the April 2014 clinical hold on HALO-202 over thromboembolic event rates, the stopped SWOG S1313 trial with a higher death rate in the PEGPH20 arm, and liver-safety concerns in the HALO 107-101 trial after hepato-biliary dysfunction was observed. It also notes that the Phase 3 HALO-301 outcome is uncertain, with approval based on PFS or OS subject to the overall benefit-risk balance.

  4. How concentrated are Halozyme's revenues?

    Roche accounted for 38% of 2017 total revenues, BMS for 32%, Alexion for 13% and Baxalta for 7%. Roche represented 63% of 2016 revenues, so the customer base has shifted toward newer collaborators.

  5. What do the debt obligations look like?

    The $150 million Royalty-backed Loan carries interest of 8.75% plus three-month LIBOR and is repaid from royalties under the Roche and Baxalta collaborations, with an estimated repayment in the first quarter of 2020. The Oxford/SVB Loan Agreement had $55.9 million outstanding at year-end 2017 and matures January 1, 2021. Total contractual long-term debt was $205.2 million, and interest on long-term debt totaled $26.8 million.